Shares of MacroGenics, Inc. (Symbol: MGNX) recently traded at $3.43, surpassing the average analyst 12-month target price of $3.40. This milestone prompts analysts to reassess their predictions, with potential changes in target prices based on recent business developments.
There are five analysts covering MacroGenics, showing a wide range of target prices from $2.00 to $5.00, resulting in a standard deviation of $1.14. Currently, the ratings breakdown includes three strong buy ratings, six hold ratings, and no sell ratings, with an average rating of 2.33, indicating a positive outlook for the stock.
This analysis is derived from data provided by Zacks Investment Research, reflecting a collective perspective on MacroGenics’ future performance.
